Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Curewell Capital is a venture capital firm based in Los Angeles, California, founded in 2021. The firm focuses exclusively on the healthcare sector, aiming to build industry-leading companies by partnering with management teams and owners. Curewell Capital has a hard cap fund size of $535 million, which was oversubscribed and closed in August 2025. The firm is dedicated to enhancing patient outcomes and driving innovation within healthcare.
As of now, Curewell Capital has established a diverse portfolio that includes notable companies such as Wilmington PharmaTech, WeInfuse, and AMR Clinical. The firm operates with a team of experienced professionals, including managing partners Michael Dal Bello and Ceron Rhee, who have extensive backgrounds in healthcare investing. Their combined experience spans over 40 years in the industry, having previously worked at Pritzker Private Capital and Blackstone.
Curewell Capital's commitment to the healthcare sector is evident in its strategic partnerships and operational improvements, which are designed to create efficiencies and improve the quality of healthcare services. The firm is actively involved in the growth of its portfolio companies, leveraging its proprietary growth framework known as GRO™.
Curewell Capital invests in various sectors within healthcare, including healthcare services, pharmaceutical services, medical devices, and healthcare technology. The firm targets essential businesses characterized by strong growth potential and defensive attributes. Their investment strategy emphasizes innovation and operational excellence, focusing on companies that enhance healthcare delivery.
In healthcare services, Curewell Capital looks for opportunities in areas such as healthcare infrastructure, outsourced services, infusion services, diagnostics, home-based services, and value-based care enablement. For pharmaceutical services, the firm seeks investments in R&D support, bioprocessing, specialty pharmacy, and commercialization, particularly in complex specialty therapeutics and devices.
In the medical devices sector, Curewell Capital focuses on clinically differentiated products that address the needs of an aging demographic, including clinician-preference devices and patient safety products. The healthcare technology sector is also a key area of interest, with investments aimed at solutions that enhance healthcare efficiency and quality outcomes, such as specialty EMR/practice management software and data analytics.
Curewell Capital's portfolio includes several notable companies that reflect its focus on the healthcare sector:
Additionally, past investments include:
Michael Dal Bello - Managing Partner. He has over 25 years of experience in principal investing, primarily in healthcare. Dal Bello previously served as an Investment Partner and Head of Healthcare at Pritzker Private Capital and has a background at Blackstone.
Ceron Rhee - Managing Partner. Rhee has over 18 years of experience investing in healthcare companies. He was an Investment Partner at Pritzker Private Capital, where he led the healthcare team, and has also worked at TPG Capital and Blackstone.
Neeraj Prathipati - Principal. Prathipati brings expertise in healthcare investments and has been instrumental in identifying growth opportunities within the sector.
Apurva Srivastav - Vice President. Srivastav supports the investment team with due diligence and portfolio management.
Tyler Lytle - Associate. Lytle assists in research and analysis of potential investment opportunities.
Christopher Kujawa - Chief Financial Officer. Kujawa oversees the financial operations of the firm, ensuring sound financial management.
Ingrid Koopman - Administrative Manager. Koopman manages administrative functions and supports the team in daily operations.
Alan Muney, MD MHA - Operating Partner. Muney has extensive experience in healthcare operations and strategy.
Kent Payne, Ph.D - Operating Partner. Payne is involved in managing portfolio companies and enhancing operational efficiencies.
David King - AMR Chairman. King provides strategic oversight for AMR Clinical.
Paula Brown Stafford - Senior Advisor & AMR Board Member. Stafford brings a wealth of experience in healthcare leadership.
George Lazenby - Senior Advisor & WeInfuse Board Member. Lazenby is also the CEO of OrderInsite.
Mike Lynch - Senior Advisor - Medical Devices. Lynch offers expertise in medical device investments.
Ken Reali - Senior Advisor - Medical Devices. Reali provides insights into the medical devices sector.
To pitch Curewell Capital, founders should send their proposals via email to info@curewellcapital.com. It is essential to include a comprehensive pitch deck that outlines the business model, market opportunity, and team qualifications. The firm appreciates detailed presentations that clearly convey the startup's value proposition and growth strategy.
Response times may vary, but founders can expect to hear back within a few weeks. Warm introductions are preferred, as they can facilitate a more favorable review of the pitch.
In August 2025, Curewell Capital announced the close of its inaugural fund, Curewell Capital I, LP, with a hard cap of $535 million. The fund was oversubscribed and completed in less than five months from launch.
The firm has been actively deploying capital across its focus areas, including healthcare services, pharmaceutical services, and medical devices. Curewell Capital is also set to exhibit at the BIO International Convention in 2026, showcasing its commitment to advancing healthcare innovation.
What are Curewell Capital's investment criteria?
Curewell Capital focuses on investing in healthcare companies across various sectors, including healthcare services, pharmaceutical services, medical devices, and healthcare technology. The firm targets essential businesses with strong growth potential and defensive characteristics, emphasizing innovation and operational excellence.
How can I apply or pitch to Curewell Capital?
Founders can pitch to Curewell Capital by sending an email to info@curewellcapital.com. It is advisable to include a detailed pitch deck that outlines the business model, market opportunity, and team background.
What makes Curewell Capital different from other investors?
Curewell Capital distinguishes itself through its exclusive focus on the healthcare sector and its proprietary growth framework known as GRO™. This framework is designed to enhance operational efficiencies and improve patient outcomes, setting the firm apart in its approach to value creation.
What is the geographic scope of Curewell Capital's investments?
The firm primarily invests in North America, specifically within the United States. This geographic focus allows Curewell Capital to leverage its deep understanding of the U.S. healthcare market.
What is Curewell Capital's fund size and check size range?
Curewell Capital has a fund size of $535 million. While specific check sizes are not disclosed, the firm typically invests in growth equity rounds, which may vary based on the company's stage and needs.
What type of post-investment involvement does Curewell Capital have?
Curewell Capital actively engages with its portfolio companies through strategic partnerships and operational improvements. The firm works closely with management teams to drive innovation and enhance efficiencies, ensuring that portfolio companies achieve their growth objectives.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.